Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 128,649 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $7.66, for a total transaction of $985,451.34. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) weekly performance is 140.49%. On last trading day company shares ended up $6.83. Analysts mean target price for the company is $5.44. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average (SMA50) is 123.19%.
ARIAD Pharmaceuticals (NASDAQ:ARIA) announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -8.69% in last trading session and ended the day on $6.41. ARIA gross Margin is 79.20% and its return on assets is -66.50%.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -14.65%.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced its scheduled presentations at the JMP Securities Healthcare Conference 2014 on Wednesday, June 25, 2014, at 12:00 p.m. ET, in New York. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares moved down -18.67% in last trading session and was closed at $7.71, while trading in range of $7.51 – $9.10. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) year to date (YTD) performance is 19.53%.
Omeros Corporation (NASDAQ:OMER) Director Thomas J. Cable sold 5,000 shares of Omeros stock on the open market in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.80, for a total value of $59,000.00. Following the completion of the sale, the director now directly owns 62,067 shares of the company’s stock, valued at approximately $732,391. Omeros Corporation (NASDAQ:OMER) ended the last trading day at $14.26. Company weekly volatility is calculated as 10.15% and price to cash ratio as 9.27.Omeros Corporation (NASDAQ:OMER) showed a positive weekly performance of 15.93%.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, on13 may announced operational and financial results for the quarter ending March 31, 2014. Net loss for the first quarter of 2014 was $10.8 million compared to a net loss of $3.8 million for the first quarter of 2013. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) weekly performance is 21.02%. On last trading day company shares ended up $19.06. Analysts mean target price for the company is $43.00. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) distance from 50-day simple moving average (SMA50) is 6.07%.
Leave a Reply